ERBB2 and breast carcinoma: Early clinical studies of trastuzumab showed significant overall survival in late-stage (metastatic) HER2-positive breast cancer from 20.3 to 25.1 months [29], and regarding early stage HER2-positive breast cancer, it reduced the risk of relapse following surgery.